Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 75382E109 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Orbimed Advisors LLC 13G/A Amendment 2 | 0% |
5/15/2026
Event 3/31/2026
|
|
|
Glazer Capital, LLC
13G
|
5.4% |
2/9/2026
Event 2/2/2026
|
|
| Glazer Capital, LLC | 5.4% | ||
| Paul J. Glazer | 5.4% | ||
| Orbimed Advisors LLC 13G/A Amendment 1 | 6.6% |
11/14/2025
Event 9/30/2025
|
|
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
0% |
11/14/2025
Event 9/30/2025
|
|
| Biotechnology Value Fund L P | 0% | ||
| BVF I GP LLC | 0% | ||
| Biotechnology Value Fund II LP | 0% | ||
| BVF II GP LLC | 0% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 0% | ||
| BVF Partners L P/IL | 0% | ||
| BVF Inc/IL | 0% | ||
| Lampert Mark N | 0% | ||
|
RTW Investments, LP
13G
|
8.9% |
5/15/2025
Event 3/31/2025
|
|
| RTW Investments, LP | 8.9% | ||
| Roderick Wong, M.D. | 8.9% | ||
| Vanguard Group Inc 13G | 6.3% |
4/30/2025
Event 3/31/2025
|
|
| BlackRock, Inc. 13G/A Amendment 4 | 1.7% |
4/25/2025
Event 3/31/2025
|
|
|
Redmile Group, LLC
13G/A
Amendment 3
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| Redmile Biopharma Investments III, L.P. | 5.4% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 5
|
4.5% |
2/14/2025
Event 12/31/2024
|
|
| Perceptive Advisors LLC | 4.5% | ||
| Joseph Edelman | 4.5% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 4.5% | ||
| Orbimed Advisors LLC 13G | 9.9% |
2/14/2025
Event 12/31/2024
|
|
| Vanguard Group Inc 13G/A Amendment 3 | 2.2% |
2/7/2025
Event 1/31/2025
|
|
| Vanguard Group Inc 13G/A Amendment 3 | 2.2% |
2/7/2025
Event 1/31/2025
|
|
|
FMR LLC
13G/A
Amendment 6
|
0.4% |
2/7/2025
Event 1/31/2025
|
|
| FMR LLC | 0.4% | ||
| Abigail P. Johnson | 0.4% | ||
|
Medicxi IV LP
13G
|
16.9% |
1/6/2025
Event 12/27/2024
|
|
| Medicxi IV LP | 16.6% | ||
| Medicxi Co-Invest IV LP | 0.3% | ||
| Medicxi IV GP Limited | 16.9% | ||
| Medicxi Ventures Management (Jersey) Limited | 16.9% | ||
|
Biotechnology Value Fund L P
13G
|
8.7% |
1/6/2025
Event 12/27/2024
|
|
| Biotechnology Value Fund L P | 4.5% | ||
| BVF I GP LLC | 4.5% | ||
| Biotechnology Value Fund II LP | 3.7% | ||
| BVF II GP LLC | 3.7% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 8.1% | ||
| BVF Partners L P/IL | 8.7% | ||
| BVF Inc/IL | 8.7% | ||
| Lampert Mark N | 8.7% | ||
|
TCG Crossover GP II, LLC
13G
|
10.0% |
1/3/2025
Event 12/27/2024
|
|
| TCG Crossover GP II, LLC | 10.0% | ||
| TCG Crossover Fund II, L.P. | 10.0% | ||
| Chen Yu | 10.0% | ||
|
Foresite Capital Fund VI LP
13G
|
9.3% |
12/30/2024
Event 12/23/2024
|
|
| Foresite Capital Fund VI, L.P. | 9.3% | ||
| Foresite Capital Management VI, LLC | 9.3% | ||
| James Tananbaum | 9.3% | ||
|
Deep Track Capital, LP
13G
|
9.9% |
12/23/2024
Event 12/23/2024
|
|
| Deep Track Capital, LP | 9.9% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 9.9% | ||
| David Kroin | 9.9% | ||
|
Column Group II, LP
13D/A
Amendment 7
|
4.9% |
12/23/2024
Event 12/23/2024
|
|
| The Column Group II, LP | 0.6% | ||
| The Column Group II GP, LP | 0.6% | ||
| Ponoi Capital, LP | 0.4% | ||
| Ponoi Management, LLC | 0.4% | ||
| Ponoi Capital II, LP | 0.5% | ||
| Ponoi II Management, LLC | 0.5% | ||
| The Column Group IV, LP | 3.9% | ||
| The Column Group IV-A, LP | 0.1% | ||
| The Column Group IV GP, LP | 4.0% | ||
| The Column Group, LLC | 0% | ||
| Peter Svennilson | 4.9% | ||
| David V. Goeddel | 4.9% | ||
| Tim Kutzkey | 4.8% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q4 | 3 | 2.96 M | $100 M |
| 2025 Q3 | 3 | 2.97 M | $76.7 M |
| 2025 Q2 | 2 | 1.34 M | $10.7 M |
| 2025 Q1 | 95 | 131 M | $160 M |
| 2024 Q4 | 97 | 127 M | $199 M |
| 2024 Q3 | 99 | 29.8 M | $59.9 M |
| 2024 Q2 | 122 | 33.0 M | $101 M |
| 2024 Q1 | 149 | 35.8 M | $322 M |
| 2023 Q4 | 122 | 37.2 M | $925 M |
| 2023 Q3 | 103 | 35.4 M | $589 M |
| 2023 Q2 | 102 | 34.1 M | $637 M |
| 2023 Q1 | 113 | 33.3 M | $611 M |
| 2022 Q4 | 100 | 34.0 M | $673 M |
| 2022 Q3 | 103 | 30.0 M | $721 M |
| 2022 Q2 | 90 | 29.7 M | $543 M |
| 2022 Q1 | 89 | 28.1 M | $618 M |
| 2021 Q4 | 112 | 30.8 M | $1.13 B |
| 2021 Q3 | 120 | 26.4 M | $818 M |
| 2021 Q2 | 134 | 29.1 M | $925 M |
| 2021 Q1 | 91 | 23.6 M | $523 M |
| 2020 Q4 | 93 | 20.4 M | $404 M |
| 2020 Q3 | 71 | 16.8 M | $542 M |
| 2020 Q2 | 56 | 15.1 M | $444 M |
| 2020 Q1 | 40 | 11.8 M | $250 M |
| 2019 Q4 | 29 | 9.17 M | $252 M |